Bayer Bundles Digital Wheat Guarantee With Drug Approvals and a Raised Outlook

Bayer CropScience Deutschland used a Thursday briefing to roll out PrediView, a digital crop-protection package aimed at the 2027 winter wheat season. The pitch rests on a straightforward promise: if growers meet the programme's conditions, the company guarantees at least 85 percent leaf health on the flag leaf. The offer ties together forecasting tools, a fungicide strategy and a written health guarantee.

A Guarantee Anchored to a Growth Stage

That 85 percent commitment applies at development stage BBCH 75, according to the company. Bayer has therefore attached the guarantee both to compliance with the programme's terms and to a defined point in the plant's development. PrediView is earmarked for the coming winter wheat campaign and builds on the existing forecasts by adding a concrete plan for fungicide use.

The crop-science launch sat alongside a pair of regulatory wins on the pharmaceutical side. The FDA cleared Bayer's Asundexian — marketed as Sunharbo — to cut the risk of a further stroke in certain adults who have suffered an ischaemic stroke or a high-risk TIA, as Reuters reported. The green light covers a new class of active ingredient and rests on positive Phase III data from OCEANIC-STROKE. In China, the NMPA approved Sevabertinib as a first-line treatment for adults with advanced HER2-mutated non-small-cell lung cancer, a decision Bayer said draws on results from the ongoing Phase I/II SOHO-01 trial. Investors greeted the FDA news by lifting the shares 3.3 percent.

Guidance Lifted as Margins and Cash Flow Improve

Financial momentum has been building since Bayer raised its full-year forecast on 3 November. The group now expects EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion, with a stronger-than-anticipated pharmaceuticals business providing the trigger, according to Reuters. Management also lifted its outlook for the Pharmaceuticals margin and for free cash flow, and it anticipates lower net financial debt.

Third-quarter 2026 figures, reported the same day, showed group revenue of EUR 10.1 billion. That represented currency- and portfolio-adjusted growth of 1.9 percent, while reported sales rose 4.1 percent. EBITDA before special items climbed 6.9 percent to EUR 1.62 billion.

Roundup Settlement Seen Before Christmas

On the long-running Roundup litigation, CEO Bill Anderson said Bayer expects to wrap up a settlement worth USD 7.25 billion before Christmas, Reuters reported. The comment came alongside the quarterly update and gives investors a timeline for one of the company's heaviest legal overhangs.

Analysts responded to the flurry of news with a higher target. Goldman Sachs lifted its price objective on Bayer to EUR 66.00 from EUR 63.50 on 4 November, keeping its "Buy" rating unchanged, according to media reports — a firmer target with the recommendation left intact.

Bayer also used 4 November to set out plans for its biologicals business in Latin America, pledging to bring 17 new biological products to the region by 2030. The line-up includes biopesticides and products designed to improve plant performance, per the Reuters account. The rollout is confined to Latin America and spans a multi-year horizon.